Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Early research (Phase 1)Looking for participantsNCT06690827
What this trial is testing

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

Who this might be right for
AML (Acute Myeloid Leukemia)BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)
Chongqing Precision Biotech Co., Ltd 30
Early research (Phase 1)Looking for participantsNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Not applicableEnded earlyNCT05645744
What this trial is testing

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Chronic Lymphocytic Leukemia in RelapseSmall Lymphocytic Lymphoma, Relapsed+8 more
Mustang Bio 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03404193
What this trial is testing

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm+12 more
M.D. Anderson Cancer Center 235
Early research (Phase 1)Looking for participantsNCT05476770
What this trial is testing

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAMLALL+8 more
Therapeutic Advances in Childhood Leukemia Consortium 54
Early research (Phase 1)Study completedNCT04681105
What this trial is testing

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Who this might be right for
Recurrent Acute LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell Neoplasm+14 more
City of Hope Medical Center 13
Early research (Phase 1)Looking for participantsNCT06712810
What this trial is testing

Q702 for the Treatment of Patients With Hematologic Malignancies

Who this might be right for
Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic 46
Very early researchLooking for participantsNCT06765876
What this trial is testing

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Who this might be right for
Leukemia, Myeloid, Acute(AML)Precursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic Syndromes (MDS)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic 18
Testing effectiveness (Phase 2)Ended earlyNCT04342962
What this trial is testing

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 25
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT03386513
What this trial is testing

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative Neoplasm
AbbVie 179
Early research (Phase 1)Looking for participantsNCT03326921
What this trial is testing

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Who this might be right for
Juvenile Myelomonocytic LeukemiaRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Undifferentiated Leukemia+26 more
Fred Hutchinson Cancer Center 24
Testing effectiveness (Phase 2)Study completedNCT00397579
What this trial is testing

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Who this might be right for
LeukemiaMyelodysplastic SyndromesBlastic Plasmacytoid Dendritic Cell Neoplasm
University of Texas Southwestern Medical Center 11
Not applicableStudy completedNCT00014235
What this trial is testing

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia/Transient Myeloproliferative DisorderAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in Remission+74 more
Fred Hutchinson Cancer Center 160
Testing effectiveness (Phase 2)Study completedNCT02220985
What this trial is testing

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Leukemia of Ambiguous Lineage+20 more
Fred Hutchinson Cancer Center 84
Testing effectiveness (Phase 2)Ended earlyNCT05086315
What this trial is testing

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Lymphocytic LeukaemiaAcute Myeloid Leukaemia RefractoryMyelodysplastic Syndromes+1 more
Sanofi 101
Early research (Phase 1)Study completedNCT01231919
What this trial is testing

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative Disorder+48 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Ended earlyNCT04109482
What this trial is testing

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Mustang Bio 3
Testing effectiveness (Phase 2)Ended earlyNCT03075553
What this trial is testing

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmHepatosplenic T-Cell LymphomaHTLV-1 Infection+14 more
Mayo Clinic 12
Testing effectiveness (Phase 2)WithdrawnNCT03739606
What this trial is testing

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Who this might be right for
Acute Biphenotypic LeukemiaAcute LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive+12 more
City of Hope Medical Center
Load More Results